ArticleInternational journal of nanomedicine2012
Hydroxyapatite nanoparticles inhibit the growth of human glioma cells in vitro and in vivo.
Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 74 citations in OpenAlex.
- SATB1 in cancer progression and metastasis: mechanisms and therapeutic potential.Frontiers in oncology · 2025Review
- Advancements in Photothermal Therapy Using Near-Infrared Light for Bone Tumors.International journal of molecular sciences · 2024Review
- Nano-hydroxyapatite promotes cell apoptosis by co-activating endoplasmic reticulum stress and mitochondria damage to inhibit glioma growth.Regenerative biomaterials · 2024Article
- Biomaterial-assisted tumor therapy: A brief review of hydroxyapatite nanoparticles and its composites used in bone tumors therapy.Frontiers in bioengineering and biotechnology · 2023Review
- Hydroxyapatite Nanoparticles for Improved Cancer Theranostics.Journal of functional biomaterials · 2022Review
- Application of osteoinductive calcium phosphate ceramics in giant cell tumor of the sacrum: report of six cases.Regenerative biomaterials · 2022Article
- Anti-melanoma effect and action mechanism of a novel chitosan-based composite hydrogel containing hydroxyapatite nanoparticles.Regenerative biomaterials · 2022Article
- Combination of Goniothalamin and Sol-Gel-Derived Bioactive Glass 45S5 Enhances Growth Inhibitory ActivityBioMed research international · 2022Article
- Study of Electron-Nuclear Interactions in Doped Calcium Phosphates by Various Pulsed EPR Spectroscopy Techniques.ACS omega · 2021Article
- The Morphology of Hydroxyapatite Nanoparticles Regulates Cargo Recognition in Clathrin-Mediated Endocytosis.Frontiers in molecular biosciences · 2021Article
- Evaluating the Radiosensitization Effect of Hydroxyapatite Nanoparticles on Human Breast Adenocarcinoma Cell Line and Fibroblast.Iranian journal of medical sciences · 2020Article
- Involvement of Bcl-2 Activation and G1 Cell Cycle Arrest in Colon Cancer Cells Induced by Titanium Dioxide Nanoparticles Synthesized by Microwave-Assisted Hybrid Approach.Frontiers in bioengineering and biotechnology · 2020Article
- Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect.Science advances · 2019Article
- Nano hydroxyapatite induces glioma cell apoptosis by suppressing NF-κB signaling pathway.Experimental and therapeutic medicine · 2019Article
- Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.Cancer gene therapy · 2018Article
- Antimicrobial Hydroxyapatite-Gelatin-Silica Composite Pastes with Tunable Setting Properties.Journal of materials chemistry. B · 2017Article
- Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor.Colloids and surfaces. B, Biointerfaces · 2016Article
- Influence of hydrothermal synthesis parameters on the properties of hydroxyapatite nanoparticles.Beilstein journal of nanotechnology · 2016Article
- Nonlinear effects of nanoparticles: biological variability from hormetic doses, small particle sizes, and dynamic adaptive interactions.Dose-response : a publication of International Hormesis Society · 2014Article
- In vitro and in vivo radiosensitization of human glioma U251 cells induced by upregulated expression of SLC22A18.Cancer gene therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxyapatite nanoparticles (nano-HAPs) have been reported to exhibit antitumor effects on various human cancers, but the effects of nano-HAPs on human glioma cells remain unclear. The aim of this study was to explore the inhibitory effect of nano-HAPs on the growth of human glioma U251 and SHG44 cells in vitro and in vivo. Nano-HAPs could inhibit the growth of U251 and SHG44 cells in a dose- and time-dependent manner, according to methyl thiazoletetrazolium assay and flow cytometry. Treated with 120 mg/L and 240 mg/L nano-HAPs for 48 hours, typical apoptotic morphological changes were noted under Hoechst staining and transmission electron microscopy. The tumor growth of cells was inhibited after the injection in vivo, and the related side effects significantly decreased in the nano-HAP-and-drug combination group. Because of the function of nano-HAPs, the expression of c-Met, SATB1, Ki-67, and bcl-2 protein decreased, and the expression of SLC22A18 and caspase-3 protein decreased noticeably. The findings indicate that nano-HAPs have an evident inhibitory action and induce apoptosis of human glioma cells in vitro and in vivo. In a drug combination, they can significantly reduce the adverse reaction related to the chemotherapeutic drug 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.